Springer Protocols: Abstract: 16. Immunotherapy With CTL Restricted by Nonself MHC

16. Immunotherapy With CTL Restricted by Nonself MHC

By: Liquan Gao³, Anne-Marie Downs³, Hans J.³

Abstract

Full Text

Download PDF (159K)

In the past years a number of target antigens recognized by cytotoxic T-lymphocytes (CTL) have been identified in human malignancies. In most cases, the CTL-recognized antigens did not arise from mutations, but were instead encoded by genes that were identical in normal and tumor cells. Gene expression in normal tissues may result in tolerance of high avidity CTL, leaving behind low avidity CTL that cannot provide effective immunity against tumors expressing the relevant target antigens. In this chapter we describe a strategy to circumvent immuno-logical tolerance that can be used to generate high avidity CTL against self-proteins, including human tumor-associated antigens.

Affiliation(s): (3) Tumour Immunology Section, Department of Immunology, Division of Medicine, Imperial College London, London, UK

Book Title: Adoptive Immunotherapy: Methods and Protocols

Series: Methods in Molecular Medicine | Volume: 109 | Pub. Date: Nov-30-2004 | Page Range: 215-228 | DOI: 10.1385/1-59259-862-5:215

Subject: Immunology

Key Words: Cytotoxic T-lymphocytes - tumor - immunotherapy - tolerance - allorestriction - avidity

References

Download References

1.	van der Bruggen, P., Traversari, C., Chomez, P., et al. (1991) A gene encoding an anti-gen recognizedby cytolytic T-lymphocytes on a human melanoma. Science 254, 1643–1647.

2.	Kawakami, Y., Eliyahu, S., Delgado, C. H., et al. (1994) Identification of human mela-noma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumorrejection. Proc. Natl. Acad. Sci. USA 91, 6458–6462.

3.	Finn, O. J. (1993) Tumor-rejection antigens recognized by T lymphocytes. Curr. Opin.Immunol. 5,701–708.

4.	Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. (1995) Targetingp53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92, 11,993–11,997.

5.	De Visser, K. E., Schumacher, T. N., and Kruisbeek, A. M. (2003) CD8+T cell toleranceand cancer immunotherapy. J. Immunother. 26, 1–11.

6.	Morris, E. C., Bendle, G. M., and Stauss, H. J. (2003) Prospects for immunotherapy ofmalignant disease. Clin. Exp. Immunol. 131, 1–7.

7.	Matzinger, P., Zamoyska, R., and Waldmann, H. (1984) Self tolerance is H-2 restrictedNature 308, 738–741.

8.	Rammensee, H. G. and Bevan, M. J. (1984) Evidence from in vitro studies that toleranceto self antigens is MHC-restricted. Nature 308, 741–744.

9.	Sadovnikova, E. and Stauss, H. J. (1996) Peptide-specific cytotoxic T lymphocytes restrictedby nonself major histocompatibility complex class I molecules: Reagents for tumor immu-notherapy. Proc. Natl. Acad. Sci. USA 93, 13,114–13,118.

10.	Obst, R., Munz, C., Stevanovic, S., and Rammensee, H. G. (1998) Allo-and self-restrictedcytotoxic T lymphocytes against a peptide library: evidence for a functionally diverseallorestricted T cell repertoire. Eur. J. Immunol. 28, 2432–2443.

11.	Munz, C., Obst, R., Osen, W., Stevanovic, S., and Rammensee, H. G. (1999) Alloreactivityas a source of high avidity peptide-specific human CTL. J. Immunol. 162, 25–34.

12.	Moris, A., Teichgraber, V., Gauthier, L., Buhring, H. J., and Rammensee, H. G. (2001)Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cellsusing HLA-tetramer selection. J. Immunol. 166, 4818–4821.

13.	Gao, L., Bellantuono, I., Elsasser, A., Marley, S. B., Gordon, M. Y., Goldman, J. M., and Stauss, H. J. (2000) Selective elimination of leukemia CD34+by CTL specific for WTI.Blood 95, 2198–2203

14.	Sadovnikova, E., Jopling, L. A., Soo, K. S., and Stauss, H. J. (1998) Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I mol-ecules. Eur. J. Immunol. 28, 193–200.

15.	Stauss, H. J. (1999) Immunotherapy with CTLs restricted by nonself MHC. Immunol.Today 20, 180–183.

16.	Mutis, T., Blokland, E., Kester, M., Schrama, E., and Goulmy, E. (2002) HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+early progenitor cells. Blood 100, 547–552.

17.	DeMars, R., Chang, C. C., Shaw, S., Reitnauer, P. J., and Sondel, P. M. (1984) Homozy-gous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autolo-gous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum. Immunol. 11,77–97.

18.	McMichael, A. J., Parham, P., Rust, N., and Brodsky, F. (1980) A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum. Immunol. 1, 121–129.

19.	Parham, P. and Bodmer, W. F. (1978) Monoclonal antibody to a human histocompatibility alloantigen HLA-A2. Nature 276, 397–399.

20.	Healey, D., Dianda, L., Moore, J. P., et al. (1990) Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+cells from virus binding. J. Exp. Med. 172, 1233–1242.

21.	Bellantuono, I., Gao, L., Parry, S., Marley, S., Dazzi, F., Apperley, J., Goldman, J. M.,and Stauss, H. J. (2002) Two distinct HLA-A0201-presented epitopes of the Wilms tu-mor antigen 1 can function as targets for leukemia-reactive CTL. Blood 100, 3835–3837.

22.	Oji, Y., Ogawa, H., Tamaki, H., et al. (1999) Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn. J. Cancer Res. 90,194–204.

23.	Menssen, H. D., Bertelmann, E., Bartelt, S., et al. (2000) Wilms’ tumor gene (WT1) expres-sion in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J. Cancer Res. Clin. Oncol. 126, 226–232.

24.	Scharnhorst, V., van der Eb, A. J., and Jochemsen, A. G. (2001) WT1 proteins: functions in growth and differentiation. Gene 273, 141–161.

Comments (Loading...)

Post comment/View all comments